Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study Meeting Abstract
| Authors: | Li, B. T.; Meric-Bernstam, F.; Bardia, A.; Naito, Y.; Siena, S.; Aftimos, P. G.; Anderson, I.; Curigliano, G.; Luken, M. J. D.; Kalra, M.; Oh, D. Y.; Park, J. O.; Postel-Vinay, S.; Rha, S. Y.; Satoh, T.; Spanggaard, I.; Michelini, F.; Smith, A.; Machado, K. K.; Manich, C. S. |
| Abstract Title: | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S459 |
| End Page: | S460 |
| Language: | English |
| ACCESSION: | WOS:001087480200639 |
| DOI: | 10.1016/j.annonc.2023.09.1840 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 654O -- Source: Wos |
